June 27, 2019: Long-term viability of NRTI-free salvage therapy; factors associated with HIV treatment interruption; evolution of frailty risk among older people; skin and soft tissue infections among people with HIV.
The link between frailty and chronic disease development; Atripla’s long-term efficacy; the dangers of restrictive eligibility criteria for hepatitis C treatment; nicotine metabolism rates in people living with HIV.
The case for a new measurement of HIV treatment success; PrEP and HIV incidence in Australia; benefits of moderate exercise among older people with HIV; CD4 recovery rates after long-term viral suppression.
Low dietary calcium might contribute to low bone mineral density (BMD) in men living with hepatitis C but not in those with HIV, according to a Veterans Administration analysis.
In a study of more than 900 middle-aged and older HIV-positive people, researchers found nearly 40% of participants were becoming physically weaker and were labelled as "pre-frail."
U.S. researchers found neurocognitive improvements over time among HIV-positive people on suppressive therapy, but also an overall risk of neurocognitive impairment that rose almost 20% every 10 years.
Overall incidence of cancers not related to infection is forecast to rise, partly because of high rates of smoking and lung cancer in people with HIV.
HIV-positive men on treatment had significantly lower cerebral blood flow than a similar group of HIV-negative men, according to results of a cross-sectional study.
In a study of HIV-positive men, frailty was linked to higher levels of inflammation markers and lower levels of testosterone and dehydroepiandrosterone (DHEA).
A recent study linked more cognitive activity to better cognitive performance in older African Americans with HIV infection.